Skip to content

Carnosine

A naturally occurring dipeptide concentrated in muscle and brain tissue, studied for anti-aging, cognitive support, and exercise performance.

CModerateWell-Studied
Last updated 20 citations
TL;DR

A dipeptide your body already makes and stockpiles in muscle and brain, sold cheaply over the counter. The strongest human evidence is metabolic — around 2 g a day moved fasting glucose and HbA1c in type 2 diabetes trials. The catch is an enzyme in your blood called carnosinase that destroys most of what you swallow within minutes, which is why athletes take beta-alanine instead when the goal is muscle carnosine, and why claims about deep tissue effects are weaker than claims about local ones.

What is Carnosine?

Carnosine (beta-alanyl-L-histidine) is a naturally occurring dipeptide found at high concentrations in skeletal muscle, heart, and brain tissue. It acts as a pH buffer during exercise, an antioxidant, an anti-glycation agent, and a metal chelator. Carnosine levels decline with age, which has driven interest in supplementation for longevity and cognitive support. It is one of the most studied dipeptides in human biology, with a strong safety profile from decades of supplement use.

What Carnosine Is Investigated For

Carnosine is an endogenous dipeptide investigated for anti-aging and anti-glycation, cognitive support, exercise performance, blood sugar regulation, and skin health — an unusually broad portfolio reflecting its multi-mechanism biology (pH buffering, anti-glycation, antioxidant, metal chelation). The strongest human evidence is metabolic, though the dose that produced it is smaller than usually quoted: 1 g/day for 12 weeks lowered fasting glucose by 13.1 mg/dL and HbA1c by 0.6% in a 54-patient type 2 diabetes RCT, while 2 g/day for 14 weeks in prediabetes and early T2DM improved post-load glucose on an oral glucose tolerance test without moving fasting glucose or insulin. Pooled syntheses disagree about which of those endpoints survives: one 2025 meta-analysis of 8 trials found reductions in both fasting glucose and HbA1c, but it pooled carnosine together with beta-alanine under a fixed-effects model, and an earlier random-effects synthesis of 4 carnosine-only RCTs found an HbA1c reduction with no effect on fasting blood sugar at all. For cognition the picture is narrower than it is usually presented — the signal is for carnosine combined with anserine or antioxidants, not carnosine alone, which showed no consistent cognitive effect across five RCTs. For exercise performance the evidence base is strong but indirect: muscle carnosine is most efficiently raised via beta-alanine supplementation rather than oral carnosine itself, because serum carnosinase rapidly hydrolyzes circulating carnosine before it reaches muscle. This bioavailability limitation is the central honest caveat — oral carnosine works best where local gut or short-exposure effects can explain the benefit, while deep systemic tissue claims rest on weaker evidence. Unlike most peptides discussed in this space, carnosine is sold as a dietary supplement with a favorable decades-long safety record and is not a prescription therapeutic.

Anti-aging and longevity (anti-glycation)
Moderate70%
Cognitive support and neuroprotection
Moderate70%
Exercise performance (pH buffering)
Moderate70%
Blood sugar and metabolic health
Emerging50%
Skin anti-aging (anti-glycation of collagen)
Emerging50%

History & Discovery

Carnosine was identified in 1900 by the Russian biochemist Vladimir Gulevich — who published as Gulewitsch — together with his student Semen Amiradjibi, working from Liebig's meat extract. The work is frequently placed at Moscow, but Gulevich held the chair of medical chemistry and physics at Kharkiv from July 1899 and was only elected to the Moscow chair in December 1900, returning there the following year; the discovery belongs to the Kharkiv period. What the pair reported was a new strongly basic organic constituent of meat extract, which they named 'carnosine' after the Latin caro (flesh) for its concentration in skeletal muscle. That it is a dipeptide — beta-alanyl-L-histidine — was established only later; at the moment of naming its structure was unknown. Shortly afterwards Friedrich Kutscher described what he believed to be a distinct base under the name ignotin, and a pointed exchange over whether the two substances were identical ran through 1906 and 1907, with Kutscher arguing that Gulewitsch's silver-salt evidence rested on impure material, before Gulewitsch's identification prevailed. That episode is why 'ignotine' still appears as an accepted synonym for carnosine in chemical registries. The peptide was subsequently recognized as endogenous to most vertebrates at millimolar concentrations in muscle, heart, and brain. Through the 20th century, carnosine research was dominated by Russian and Eastern European laboratories, who identified its roles in pH buffering during exercise, antioxidant activity, and chelation of transition metals. In the 1990s interest broadened to anti-glycation biology — the observation that carnosine scavenges the reactive carbonyl species that form advanced glycation end-products — which repositioned it as a candidate in longevity and diabetic-complication research. Commercially, carnosine has always lived on the supplement side of the regulatory line: oral L-carnosine is widely sold in the US and internationally as a dietary supplement, and N-acetyl-carnosine eye drops for cataracts (developed largely out of Russian research) have a much weaker US evidence base. Carnosine has not been pursued as a prescription drug in the US, and the 'peptide therapeutic' framing that applies to injectable peptides like BPC-157 or Tα1 does not apply here — carnosine is a category-different product. One specific product niche has developed more clinical traction: zinc-L-carnosine complex (originally studied in Japan for gastric ulcer) — a 2026 Dent J systematic review and meta-analysis (PMID 42505716) pooled 8 studies (n = 544) on oral mucosal injury. Read carefully, it is weaker than it sounds: severe oral mucositis was reduced under a common-effect model (OR 0.48, 95% CI 0.32–0.72) but the result did not hold under random effects (OR 0.44, 95% CI 0.18–1.06), six of the eight studies were non-randomised with moderate-to-serious risk of bias, and GRADE certainty was low for mucositis and very low for mucosal healing. It is a promising niche, not an established use case.

How It Works

Carnosine protects your cells in multiple ways: it buffers acid buildup during exercise (preventing fatigue), blocks sugar molecules from damaging proteins (a key aging process called glycation), neutralizes free radicals, and chelates excess metals that can cause cellular damage.

Carnosine operates through several independent mechanisms: (1) pH buffering — its imidazole ring has a pKa near physiological pH, making it an effective intracellular buffer during anaerobic exercise; (2) anti-glycation — it scavenges reactive carbonyl species (methylglyoxal, glyoxal) that form advanced glycation end-products (AGEs), a hallmark of aging and diabetic complications; (3) antioxidant — it directly quenches reactive oxygen species and reactive nitrogen species, and chelates pro-oxidant transition metals (Cu²⁺, Zn²⁺, Fe²⁺); (4) neuroprotection — it modulates glutamatergic neurotransmission, reduces neuroinflammation, and protects against amyloid-beta toxicity in vitro. A 2026 Curr Neuropharmacol systematic review (PMID 42695325) synthesizes the mechanistic and pharmacological perspectives on L-carnosine's vascular and neuronal roles as they stand at mid-decade. Serum carnosinase (CN1) rapidly hydrolyzes circulating carnosine, which is a key pharmacokinetic limitation of oral supplementation.

Evidence Snapshot

Overall Confidence65%

Human Clinical Evidence

Moderate. RCTs supporting benefits in exercise performance (via beta-alanine), diabetes/metabolic health, cognitive function in elderly, and autism. A 2026 systematic review and meta-analysis (Tufts) of 13 distinct studies (12 RCTs and one single-arm trial) concluded that L-carnosine combined with anserine or antioxidants significantly improved MMSE scores in elderly and Alzheimer's-spectrum patients (pooled net change 0.62, 95% CI 0.23–1.01), while carnosine monotherapy showed no consistent cognitive signal — strength of evidence was rated low. The trials this page previously described as ongoing for Alzheimer's, diabetic nephropathy and Gulf War illness have all completed. The Gulf War illness trial (25 participants, 500 to 1,500 mg escalating over 12 weeks) was largely negative: WAIS-R digit-symbol scores rose and IBS-associated diarrhoea fell, but "fatigue, pain, hyperalgesia, activity and other outcomes were resistant to treatment." The live interventional work has moved to peripheral arterial disease.

Animal / Preclinical

Strong. Extensive preclinical data on anti-glycation, neuroprotection, lifespan extension in animal models, and diabetic complications.

Mechanistic Rationale

Very strong. Anti-glycation, pH buffering, and antioxidant mechanisms are well-characterized at the molecular level.

Research Gaps & Open Questions

What the current literature has not yet settled about Carnosine:

  • 01Human bioavailability of oral carnosine at different doses and formulations — despite decades of research, systematic pharmacokinetic characterization of oral carnosine across the population (including carnosinase polymorphisms) is thin. A 2026 J Int Soc Sports Nutr placebo-controlled RCT (PMID 42308284) finally tested oral carnosine itself on physical function in 299 people at 2 g/day, and the result is equivocal in an informative way: there was no significant difference on any measure overall, but two subgroup signals emerged — more bilateral calf raises to exhaustion at 6 weeks in participants under 40 (p = 0.018) and more steps on the 2-minute step test at 12 weeks in men over 40 (p = 0.010). The authors concluded that benefit appears "in select age groups" and "limited to males." Subgroup findings without an overall effect are the weakest form of positive result, so this neither rescues oral carnosine for performance nor closes the bioavailability question — but the page can no longer describe oral carnosine as having no functional effect at all.
  • 02Anti-aging claims at the tissue level — animal evidence for lifespan extension and anti-glycation is reasonable, but human data specifically linking carnosine supplementation to clinically meaningful anti-aging endpoints (cardiovascular, renal, neurologic) is limited. Fresh 2026 mechanism work extends the biological rationale — a Biology 2026 mouse study (PMID 42450547) mapped carnosine's PI3K/AMPK/PGC-1α signaling in T2D sarcopenia, and a J Am Heart Assoc 2026 paper (PMID 42432441) described carnosinylation of cardiac antigens attenuating immunogenic responses and improving function in failing hearts — though note that study raised myocardial carnosine by feeding mice beta-alanine in drinking water, not by giving carnosine, which is the same delivery logic the exercise literature uses. Human clinical translation of these mechanisms is still absent.
  • 03Optimal formulation — sustained-release, carnosinase-resistant analogs, and liposomal preparations are being developed, but head-to-head comparisons with plain oral carnosine in human trials are largely absent.
  • 04Long-term (multi-year) safety and efficacy — most trials run 8–24 weeks; multi-year data is essentially anecdotal from general supplement use.
  • 05Topical and cosmetic anti-glycation claims — the in vitro biology is real, but skin-penetration and endpoint trials for cosmetic carnosine products are limited.
  • 06N-acetyl-carnosine for cataracts — Russian research supports a modest benefit; independent Western replication is weak, and the US regulatory pathway has not been pursued.

Forms & Administration

Oral supplementation, typically 500-2000mg per day in divided doses. Available as capsules, tablets, and powder. No prescription required. Beta-alanine (2-5g/day) is an alternative for raising muscle carnosine levels. Sustained-release and carnosinase-resistant formulations are emerging to improve bioavailability.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

Oral L-carnosine supplementation in published human trials has most commonly used 500–2,000 mg per day, with trial protocols for diabetes (1 g/day in the trial that lowered fasting glucose and HbA1c; 2 g/day in the trial that moved post-load glucose only), cognitive support in older adults (roughly 1.5 g/day), and autism (800 mg/day for 8 weeks in the Chez pediatric trial) clustering in that range. Exercise-performance work generally uses beta-alanine (the rate-limiting precursor) at 3.2–6.4 g/day rather than carnosine itself, because oral carnosine is rapidly hydrolyzed by serum carnosinase before it reaches muscle. Topical anti-glycation cosmetic formulations use much lower concentrations, typically 0.5–2%.

Frequency

Oral carnosine is typically dosed in 2–3 divided doses with or without food. Beta-alanine for muscle-loading purposes is also split across the day, primarily to minimize the paresthesia (tingling) that comes with larger single doses. N-acetyl-carnosine eye drops, where used, follow product-specific instructions (commonly one to two drops per eye twice daily).

Timing Considerations

No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.

Cycle Length

For exercise performance, beta-alanine loading protocols run 4–12 weeks; muscle carnosine content rises slowly and plateaus around 8–12 weeks of consistent use. For anti-aging, metabolic, and cognitive applications, continuous daily use is the typical pattern, and no formal cycling strategy is established. There is no strong rationale for scheduled breaks.

Protocol Notes

The central pharmacokinetic issue is serum carnosinase (CN1), a human enzyme that hydrolyzes circulating carnosine within minutes. Most orally ingested carnosine never reaches peripheral tissues intact, which is why beta-alanine (which bypasses carnosinase, enters muscle, and is intracellularly conjugated to histidine to form carnosine) dominates the exercise-performance literature. For anti-glycation effects at the gut-tissue interface, intact oral carnosine is more defensible; for systemic effects on muscle, brain, or diabetic kidney tissue, the pharmacologic picture is less clean. Sustained-release formulations and carnosinase-resistant analogs (such as carnosine-histidine conjugates, or modifications like anserine and N-acetyl-carnosine) are under active investigation to address this bioavailability problem. For now, the honest picture is that oral carnosine supplementation has the strongest evidence where local gut or short-exposure effects can explain the benefit, and a weaker case where deep peripheral tissue effects are the claim. Carnosine is remarkably well tolerated at the doses studied. The most common side effect of beta-alanine — but not carnosine itself — is a transient tingling sensation from histidine-receptor activation. Carnosine's safety record across decades of supplement use is favorable.

Oral carnosine is sold as a dietary supplement under DSHEA; it is not FDA-approved as a drug and supplement claims are regulated differently from drug claims. Those on diabetes medication should involve their clinician because of potential additive blood-sugar effects.

Timeline of Effects

Onset

Exercise-performance effects from beta-alanine loading (raising muscle carnosine) emerge only after weeks of consistent dosing — muscle carnosine rises slowly because of the slow intracellular buildup. Oral carnosine itself produces no reliable acute effect in the usual exercise-performance sense, given carnosinase degradation; the one large trial of oral carnosine on physical function found nothing at 6 or 12 weeks except in two age-and-sex subgroups. For metabolic and cognitive endpoints, human trials typically begin showing effects over 8–12 weeks of daily dosing.

Peak Effect

Muscle carnosine plateaus at roughly 8–12 weeks of beta-alanine loading and remains elevated with continued dosing. Published cognitive and metabolic endpoints (HbA1c improvement, memory scores) have typically reached peak measured effect by 12 weeks in randomized trials. Anti-glycation effects on skin and collagen, where claimed, would unfold on the much longer timescale of tissue turnover.

After Discontinuation

After stopping beta-alanine, muscle carnosine falls at roughly 2–4% per week, and the figures often quoted as a "half-life" are in fact complete washout times — which makes the pool sound twice as persistent as it is. In the original MRS study, muscle carnosine was back to baseline within 9 weeks at group level, with full washout taking 15 weeks in high responders and 6 weeks in low responders. A later 16-week study using a higher beta-alanine dose tracked the decay more finely (+59%, +35%, +18% and −3% of baseline at 4, 8, 12 and 16 weeks) and found muscle carnosine statistically indistinguishable from baseline from week 12 onward. The honest range is roughly 6 to 16 weeks to complete washout, depending on dose and how big the loading response was — slow to load and slow to unload, but not indefinitely so. Effects on glucose control, cognitive measures, and markers of glycation would be expected to regress similarly over weeks to months. Rebound effects have not been described; this is a supplement with a gentle pharmacodynamic footprint.

Common Questions

What's the difference between carnosine and beta-alanine?

Beta-alanine is an amino acid precursor that your body uses to make carnosine. Most exercise studies use beta-alanine because it's the rate-limiting factor for carnosine synthesis. Supplementing carnosine directly is preferred for anti-aging and cognitive benefits, as it acts on different pathways than just muscle pH buffering.

Is carnosine a peptide?

Yes. Carnosine is a dipeptide — the simplest type of peptide, made of just two amino acids (beta-alanine and histidine). Unlike most peptides discussed in this space, it is widely available as an oral supplement.

Why do carnosine levels decline with age?

Carnosine is broken down by the enzyme carnosinase in the blood. Carnosinase activity increases with age, reducing circulating carnosine. Muscle carnosine also declines due to reduced synthesis and lower physical activity.

Does carnosine actually lower blood sugar?

Modestly, and the detail matters because the dose usually quoted is wrong. The trial that moved both fasting glucose and HbA1c used 1 g/day, not 2 g/day: 54 patients with type 2 diabetes took two 500 mg capsules daily for 12 weeks and saw fasting glucose fall 13.1 mg/dL and HbA1c fall 0.6% against placebo. A separate trial using 2 g/day for 14 weeks in prediabetes and early type 2 diabetes improved glucose at 90 and 120 minutes on an oral glucose tolerance test and total glucose area under the curve, but left fasting glucose, HbA1c and insulin unchanged — which points at hepatic glucose output rather than insulin secretion. Meta-analyses split on fasting glucose and agree on HbA1c. So: a real but small effect, concentrated in post-meal glucose, not a replacement for diabetes medication, and worth telling your clinician about if you take insulin or a sulfonylurea because the effects are additive.

Do N-acetyl-carnosine eye drops reverse cataracts?

Russian research supports a modest benefit on early senile cataract, but independent Western replication is weak and the FDA has not approved them for cataract treatment. No major ophthalmic society recommends them as standard therapy — established cataract treatment remains surgical. Patients with cataracts should consult an ophthalmologist rather than self-treating with these drops.

Who Carnosine Is NOT For

Contraindications
  • •Carnosinemia (serum carnosinase deficiency) and other rare histidine metabolism disorders — supplementation can cause unphysiologic accumulation and should be avoided without specialist input.
  • •Concurrent high-dose insulin or sulfonylurea therapy without clinician coordination — carnosine can additively lower blood glucose; insulin or sulfonylurea doses may need adjustment.
  • •Pregnancy and breastfeeding — normal dietary exposure is unremarkable, but high-dose supplementation has not been formally studied; conservative default is to avoid pharmacologic supplement doses.
  • •Known hypersensitivity to carnosine or to supplement-matrix components (excipients, flow agents, capsule materials).
  • •Pediatric use at adult doses — pediatric studies have used lower doses (e.g., 400–800 mg/day in autism research); adult doses should not be extrapolated to children without clinician oversight.
  • •Do not inject oral-supplement-grade carnosine — these products are not sterile injectables and there is no clinical rationale for injection.

Drug & Supplement Interactions

Carnosine has a relatively clean drug-interaction profile reflecting its endogenous origin and short systemic residence time, but a few categories warrant attention. The most clinically meaningful consideration is with glucose-lowering medication. Carnosine at 1 g/day lowered fasting glucose and HbA1c in a type 2 diabetes trial, and 2 g/day lowered post-load glucose in prediabetes; patients on insulin, sulfonylureas, or other agents with hypoglycemic potential should monitor for additive effects and coordinate dose changes with their prescribing clinician. The risk is modest, but the interaction is mechanistically plausible and was observable in trials. Carnosine chelates divalent cations (zinc, copper, iron), so high-dose supplementation taken simultaneously with mineral supplements or mineral-dependent medications (iron supplements for anemia, zinc-heavy multivitamins) may reduce absorption of both — separating timing by a few hours is a reasonable precaution. The relationship with ACE inhibitors runs the opposite way from how it is often stated: carnosine is itself described in the renal literature as a natural angiotensin-converting-enzyme inhibitor, so the theoretical concern is additive ACE inhibition on top of a prescribed ACE inhibitor, not an ACE inhibitor prolonging carnosine. We could find no evidence that ACE inhibitors inhibit serum carnosinase — one rat study of lisinopril reported no effect on carnosinase-1 concentration at all. Neither direction has been shown to matter clinically at supplement doses. Patients on any regular medication, particularly for diabetes, should disclose carnosine use to their clinician.

Safety Profile

Safety Information

Common Side Effects

Generally very well-toleratedRare: mild tingling or paresthesia (more common with beta-alanine)Occasional mild GI discomfort

Cautions

  • • Very safe even at high doses in studies
  • • Those with histidine metabolism disorders should consult a physician
  • • May interact with certain diabetes medications (additive blood sugar lowering)

What We Don't Know

Oral carnosine is rapidly broken down by serum carnosinase, which limits bioavailability. Strategies to improve this (sustained-release formulations, carnosinase-resistant analogs) are under investigation.

Myths & Misconceptions

Myth

Taking oral L-carnosine is the best way to raise muscle carnosine for exercise performance.

Reality

It is not. Oral carnosine is rapidly hydrolyzed by serum carnosinase and does not efficiently reach muscle intact. Muscle carnosine is most effectively raised by supplementing beta-alanine (the rate-limiting precursor), which enters muscle and is intracellularly conjugated to histidine. Exercise-performance studies use beta-alanine for this reason. One honest qualification: a 299-person 2026 RCT of oral carnosine at 2 g/day found no overall effect on physical function but did find endurance improvements in two subgroups of men, so "oral carnosine does nothing for performance" is slightly stronger than the evidence now supports. What remains true is that if raising muscle carnosine is the goal, beta-alanine is the efficient route.

Myth

Carnosine is a prescription peptide therapeutic.

Reality

Carnosine is an endogenous dipeptide sold as a dietary supplement under DSHEA in the US, and in similar regulatory frameworks abroad. It is not a drug, not FDA-approved for any indication, and is not injected in clinical use. The 'peptide therapeutic' framing that applies to BPC-157 or Thymosin Alpha-1 does not apply here — it is a different regulatory and clinical category.

Myth

Carnosine reverses aging by eliminating AGEs.

Reality

Carnosine is a well-characterized scavenger of reactive carbonyl species that contribute to advanced glycation end-product formation, and in vitro and animal evidence is reasonable. Translating that into 'reverses aging' overstates human evidence substantially. Human trials show modest benefit on specific endpoints (glucose control, cognitive measures in older adults) and do not establish a wholesale anti-aging effect.

Myth

N-acetyl-carnosine eye drops reverse cataracts.

Reality

N-acetyl-carnosine drops have Russian research supporting a modest effect on early senile cataract and a much weaker evidence base in independent Western trials. No major ophthalmic society recommends them as a standard therapy, and established cataract treatment remains surgical. Patients with cataracts should consult an ophthalmologist rather than relying on these drops.

Myth

Higher doses of oral carnosine produce proportionally better results.

Reality

Above roughly 1–2 g/day in divided doses, the rate-limiting factor is serum carnosinase rather than ingested amount. Doubling the dose does not double systemic exposure. If the goal is muscle carnosine, beta-alanine is the more efficient pathway; if the goal is gut-level or local effects, moderate oral doses are reasonable.

Published Research

20 studies

A Systematic Review of the Vascular and Neuronal Role of L-Carnosine: Mechanistic and Pharmacological Perspectives.

Systematic ReviewPMID: 42695325

Protective and Healing Effects of Zinc L-Carnosine on the Oral Mucosa: A Systematic Review and Meta-Analysis.

Meta-AnalysisPMID: 42505716

The Role and Mechanism of Carnosine in Alleviating Type 2 Diabetic Sarcopenia in Mice Through PI3K/AMPK/PGC-1α Signaling Pathway.

PreclinicalPMID: 42450547

Carnosinylation of Cardiac Antigens Attenuates Immunogenic Responses and Improves Function in Failing Hearts.

PreclinicalPMID: 42432441

Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.

J Int Soc Sports Nutr 2026 placebo-controlled RCT, 299 participants on oral carnosine 2 g/day for 12 weeks — the first large test of carnosine itself rather than beta-alanine on physical function. No significant difference on any measure overall; significant gains only in two subgroups (calf raises at 6 weeks in under-40s, 2-minute step test at 12 weeks in men over 40), with the authors concluding benefit was limited to males.

Randomized Controlled TrialPMID: 42308284

The effects of carnosine on cognitive function and mental health — a systematic review and meta-analysis

2026 Tufts meta-analysis of 13 distinct studies (12 RCTs and one single-arm trial) finding L-carnosine combined with anserine or antioxidants modestly improves MMSE scores in elderly and Alzheimer's-spectrum patients; carnosine monotherapy shows no consistent cognitive signal across five RCTs.

ReviewPMID: 42123986

CNDP1 (CTG)5 allele and cardiovascular events in high-risk patients: LURIC study results

Observational CohortPMID: 42014802

Effect of carnosine or beta-alanine supplementation therapy for prediabetes or type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Meta-AnalysisPMID: 40999397

Carnosine supplementation improves glucose control in adults with pre-diabetes and type 2 diabetes: A randomised controlled trial

Randomized Controlled TrialPMID: 38172006

Kinetics of Muscle Carnosine Decay after beta-Alanine Supplementation: A 16-wk Washout Study

Randomized Controlled TrialPMID: 33148972

Effect of carnosine supplementation on lipid profile, fasting blood glucose, HbA1C and insulin resistance: A systematic review and meta-analysis of long-term randomized controlled trials

Meta-AnalysisPMID: 31987255

l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-alpha levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial

Houjeghani and colleagues, Nutrition Research 2018. The trial behind this page's blood-sugar claim, and the reason the dose is often misquoted: 54 patients with type 2 diabetes took two 500 mg capsules daily — 1 g/day, not 2 — for 12 weeks, with fasting glucose falling 13.1 mg/dL and HbA1c 0.6% against placebo, alongside reductions in triglycerides, carboxymethyl lysine and TNF-alpha.

Randomized Controlled TrialPMID: 29420997

Carnosine and anserine homeostasis in skeletal muscle and heart is controlled by beta-alanine transamination

PreclinicalPMID: 27062388

Carnosine and related peptides: Therapeutic potential in age-related disorders

Review of carnosine's anti-glycation and anti-aging properties, including evidence for protection against AGE-mediated tissue damage in diabetic complications.

ReviewPMID: 26425391

International society of sports nutrition position stand: Beta-Alanine

Comprehensive position paper confirming beta-alanine (carnosine precursor) supplementation improves exercise capacity, particularly in 1-10 minute high-intensity efforts.

ReviewPMID: 26175657

Carnosine treatment for gulf war illness: a randomized controlled trial

Randomized Controlled TrialPMID: 23618477

Carnosine loading and washout in human skeletal muscles

Baguet and colleagues, J Appl Physiol 2009. The source of the washout numbers this page previously reported as a half-life. Muscle carnosine measured by proton MRS in soleus, tibialis anterior and gastrocnemius after 5–6 weeks of beta-alanine: content rose 23–39% and then declined at 2–4% per week, returning to baseline within 9 weeks at group level, with complete washout taking 15 weeks in high responders and 6 weeks in low responders.

Randomized Controlled TrialPMID: 19131472

The effect of beta-alanine supplementation on neuromuscular fatigue in elderly (55-92 Years): a double-blind randomized study

Randomized Controlled TrialPMID: 18992136

Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1

Genetic Association StudyPMID: 16046297

Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders (Chez et al., J Child Neurol 2002)

Randomized Controlled TrialPMID: 12585724

Quick Facts

Class
Endogenous Dipeptide
Tier
C
Evidence
Moderate
Safety
Well-Studied
Updated
Nov 2026
Citations
20PubMed

Also known as

L-CarnosineBeta-Alanyl-L-HistidineIgnotine

Tags

LongevityAnti-AgingCognitiveExerciseAntioxidant

Evidence Score

Overall Confidence65%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.